Effects of 100% Orange Juice on Skin Health in Women

February 6, 2024 updated by: University of Florida

A Pilot Clinical Trial to Assess the Effects of 100% Orange Juice on Skin Health in Women Using a Randomized Double-Blinded Placebo-Controlled Crossover Design

Daily consumption of Orange Juice (OJ) protects skin against UV-induced damages and wrinkling, improves skin barrier function and overall skin health by decreasing oxidative stress, inflammation, and protein glycation. The positive effects of OJ on skin appearance are associated with improvements of the stratum corneum lipidomic and skin microbiome.

Study Overview

Status

Recruiting

Conditions

Detailed Description

There is a lack of clinical evidence on how 100% orange juice (OJ) affects skin health. Women make over 90% of the decisions on food purchases for family. Skin health is a major concern for women because skin ageing becomes visibly noticeable after age 30 due to UV exposure, oxidative stress, and collagen glycation. The investigators hypothesize that micronutrients in OJ, including vitamin C, flavanones, and carotenoids, protect skin against photoaging and wrinkling by alleviating oxidative stress, inflammation, and collagen glycation. The investigators further propose that daily OJ consumption (16 oz) will improve skin elasticity, barrier function, overall skin appearance and health. The study hypotheses will be tested in a 12-week clinical trial in 24 women aged 45-65 using a randomized, double-blinded, placebo-controlled, crossover design. Placebo will be formulated using decarbonated Fanta® orange soda to match the color, taste, and calorie content of OJ, but will contain no micronutrients. This research will measure UV-induced skin erythema, wrinkles, smoothness, roughness, elasticity, hydration, pH, melanin, and transepidermal water loss (a skin barrier index) of skin on both face and forearm. Skin strips and swabs will be collected and preserved for future assessments of skin lipids and colonized microorganisms (skin microbiome) because they are key factors affecting skin health. Positive results from this pilot trial will provide clinical evidence on the effectiveness of OJ to maintain skin health and reduce ageing. This research will be carried out by a research team with the experience and facilities for skin research.

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Yavuz Yagiz, PhD
  • Phone Number: (352) 294-3988
  • Email: yavuzy@ufl.edu

Study Contact Backup

  • Name: Liwei Gu, PhD
  • Phone Number: (352) 294-3730
  • Email: lgu@ufl.edu

Study Locations

    • Florida
      • Gainesville, Florida, United States, 32611
        • Recruiting
        • Food Science and Human Nutrition Department at University of Florida
        • Contact:
          • Yavuz Yagiz
        • Contact:
          • Liwe Gu
        • Principal Investigator:
          • Liwei Gu, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • BMI (18.5-29.9)
  • Body weight ≥110 pounds
  • Fitzpatrick skin type 2 and 3.

Exclusion Criteria:

  • pregnancy
  • breast-feeding
  • impaired fasting glucose
  • frequent alcohol use
  • history of skin cancer
  • sunbathing and the use of tanning bed, intake of vitamin/mineral supplements
  • habitual high intake of fruits (≥ 2 cups daily)
  • intake of medication that might influence the outcome of the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Orange Juice then Placebo juice (Fanta)
Participants will be provided orange juice for 84 days in this arm. After 28 days wash-out period, participants will receive Fanta for 84 days.
Orange juice will be purchased commercially.
Fanta will be purchased commercially.
Active Comparator: Placebo (Fanta) then Orange juice
Participants will be provided Fanta for 84 days in this arm. After 28 days wash-out period, participants will receive Orange juice for 84 days.
Orange juice will be purchased commercially.
Fanta will be purchased commercially.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline Skin color change after UV irradiation at 84 days
Time Frame: Baseline, 84 days
Irradiation will be applied to dorsal skin (back, scapular region not typically exposed to the sun) with 2 times of minimal erythema dose using an FDA approved UVB phototherapy light and a UV light meter. At baseline, after 42 and 84 days, skin color will be measured before and 24 hours after irradiation. Skin color will be evaluated by a colorimeter using the 3-dimensional color system with L*, a*, and b*-values. L* and b* values assess lightness and browning effects, respectively. The a*-value (red/green-axis) is a measure for reddening (erythema).
Baseline, 84 days
Change from baseline skin transepidermal water loss
Time Frame: Baseline, 84 days
Skin transepidermal water loss will be measured using a Tewameter to evaluate the water barrier function of the skin. The Tewameter measures the density gradient of the water evaporation from the skin (g/h/m^2).
Baseline, 84 days
Change from baseline skin erythema and melanin index
Time Frame: Baseline, 84 days
Skin erythema and melanin index will be assessed with Mexameter. These two components are mainly responsible for the color of the skin. They are measured by reflectance.
Baseline, 84 days
Change from baseline skin pH plus
Time Frame: Baseline, 84 days
Skin pH will be measured using a Skin-pH-Meter.
Baseline, 84 days
Change from baseline skin hydration
Time Frame: Baseline, 84 days
Skin hydration will be measured using a Skin Corneometer.
Baseline, 84 days
Change in skin microbiome
Time Frame: Baseline, 84 days
For skin swabbing, a 3x3-cm square on a forearm will be swabbed with a cotton swab soaked in 0.9% sodium chloride with 0.1% Tween-20 in a Z-stroke manner.
Baseline, 84 days
Change in DNA damages
Time Frame: Baseline, 84 days
Urinary excretion of 8-oxo-2'-deoxyguanosine (8-oxo-dG) will be assessed using HPLC-MS/MS because it has been suggested as a sensitive marker for UV induced skin DNA damages.
Baseline, 84 days
Change in oxidative stress
Time Frame: Baseline, 84 days
Malondialdehyde in plasma will be determined as a marker of lipid peroxidation using a photometric method.
Baseline, 84 days
Change in inflammation
Time Frame: Baseline, 84 days
Plasma levels of IL-6 proteins will be analyzed as inflammation biomarkers using ELISA kits.
Baseline, 84 days
Change in inflammation
Time Frame: Baseline, 84 days
Plasma levels of C-reactive proteins will be analyzed as inflammation biomarkers using ELISA kits.
Baseline, 84 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 4, 2023

Primary Completion (Estimated)

October 1, 2024

Study Completion (Estimated)

December 1, 2024

Study Registration Dates

First Submitted

April 20, 2021

First Submitted That Met QC Criteria

April 26, 2021

First Posted (Actual)

April 27, 2021

Study Record Updates

Last Update Posted (Actual)

February 7, 2024

Last Update Submitted That Met QC Criteria

February 6, 2024

Last Verified

August 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • IRB202100814

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Skin Health

Clinical Trials on Orange juice

3
Subscribe